Skip to search formSkip to main contentSkip to account menu

MEDI-538

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

blinatumomab

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2008
2008
Bioavailability, pharmacodynamic activity, and anti-tumor efficacy of the CD19/CD3-specific BiTE antibody MEDI-538 (MT103) delivered subcutaneously in animal models
2131 MEDI-538 (MT103) is a bispecific single-chain, T cell-engaging (BiTE) antibody that targets CD19+ B cells and recruits CD3… 
2007
2007
The Anti-CD19 Bispecific T-Cell Engager (BiTE) MT103 (MEDI-538), Induces Dose-Dependent Complete and Partial Responses in Relapsed Non-Hodgkin Lymphoma (NHL): Phase I Study MT103-104.
MT103 (MEDI-538), a bispecific, single chain construct specific for CD19 and CD3, is a member of a novel class of highly active… 
2006
2006
The Bi-Specific T-Cell Enhancer (BiTE) MT103 (MEDI-538) Induces Clinical Responses in Heavily Pre-Treated NHL Patients: Update from the Ongoing Phase I Study MT103-104.
MT103 is a bispecific single-chain (anti-CD19/anti-CD3) antibody derivate designed to link B-cells and T-cells. Preclinical… 
2006
2006
T Cell Responses during Long-Term Continuous Infusion of MT103 (MEDI-538; Anti-CD19 BiTE) in Patients with Relapsed B-NHL: Data from Dose-Escalation Study MT103-104.
MT103 (MEDI-538) is a bispecific single-chain antibody construct directed at CD3 on human T cells and CD19 on human B lymphoma… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)